50 research outputs found
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (40âmgâmâ2) for 5 weeks concurrent with upper abdominal radiation (50.4âGy in 5Âœ weeks). At the completion of the chemoradiation, patients without disease progression were given gemcitabine (1000âmgâmâ2) weekly for two cycles. Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment. Forty-seven patients were entered, 46 of whom are included in this analysis. Characteristics: median age 61 years (range 35â79); 24 females (58%); 73% stage T3/T4; and 70% lymph node positive. Grade III/IV gastrointestinal or haematologic toxicities were infrequent. The median survival was 18.3 months, while the median time to disease recurrence was 10.3 months. Twenty-four percent of patients were alive at 3 years. Only six of 34 patients with progression experienced local regional relapse as a component of the first site of failure. These results confirm the feasibility of delivering adjuvant concurrent gemcitabine and radiation to the upper abdomen. This strategy produced good local regional tumour control
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (40âmgâmâ2) for 5 weeks concurrent with upper abdominal radiation (50.4âGy in 5Âœ weeks). At the completion of the chemoradiation, patients without disease progression were given gemcitabine (1000âmgâmâ2) weekly for two cycles. Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment. Forty-seven patients were entered, 46 of whom are included in this analysis. Characteristics: median age 61 years (range 35â79); 24 females (58%); 73% stage T3/T4; and 70% lymph node positive. Grade III/IV gastrointestinal or haematologic toxicities were infrequent. The median survival was 18.3 months, while the median time to disease recurrence was 10.3 months. Twenty-four percent of patients were alive at 3 years. Only six of 34 patients with progression experienced local regional relapse as a component of the first site of failure. These results confirm the feasibility of delivering adjuvant concurrent gemcitabine and radiation to the upper abdomen. This strategy produced good local regional tumour control
The role of thin needle percutaneous guided puncture in the diagnosis of cancer of the pancreas
Le guidage a été réalisé soit par échographie en temps réel, soit par tomodensitométrie, soit par radioscopie télévisée. La biopsie percutanée à l'aiguille fine apparaßt comme une méthode simple, peu onéreuse, efficace et fiable pour établir le diagnostic préopératoire de cancer du pancréa
Etude sur quatre ans des cas de yersiniose dans un service d'hépato-gastro-entérologie de la région lyonnaise
International audienc
Contribution of proximal endoscopy in chronic diarrhea associated with immuno-deficiency
a L'apport de l'entÚroscopie dans la mise en évidence de l'étiologie des diarrhées chroniques par déficit immunitaire été précisé par une étude rétrospective portant sur 225 malades. Un délicit de l'immunité humorale, global ou sélectif, a été constaté chez 8 malades. L'étude indique que l'observation d'une atrophie villositaire et/ou d'une hyperplasie nodulaire lymphoïde constituent des signes d'appels. La découverte grùce à l'entéroscopie d'une lambliase méconnue apporte des arguments identiques. La connaissance de l'existence d'un déficit sérique en IgA ne dispense pas de l'entéroseopie et de la numération des plasmocytes muqueux compte tent d'une possible absence de concordance entre immunité locale et immunité systémique